FORWARD: Sprifermin yields durable structural improvements in knee OA
27 May 2021
byJairia Dela Cruz
In patients in knee osteoarthritis (OA), the disease-modifying OA drug sprifermin produces a favourable change in articular cartilage, which is sustained for more than 3 years after treatment, according to 5-year data from the FORWARD* trial.